Megan’s Mission Foundation donated $70,000 to Children’s Cancer Therapy Development Institute to continue supporting two research studies for Rhabdomyosarcoma. This funding furthers cc-TDI’s initial work into two key areas – the continued testing of FDA approved drugs for efficacy on treating Rhabdomyosarcoma (RMS) and furthering immunotherapy as a therapy option for alveolar and embryonal RMS. For more information about this important work, visit Children’s Cancer Therapy Development Institute. The complete press release is available at Furthering Megan’s Mission.